China Resources Biomedical

About China Resources Biomedical

China Resources Biopharmaceutical Co. Ltd. (CR Biopharm) is a biopharmaceutical entity established in 2016 as a non-wholly owned subsidiary of China Resources Pharmaceutical Group Ltd. . The company operates within the broader China Resources ecosystem, a state-owned enterprise with deep roots in Hong Kong and mainland China since 1938 . CR Biopharm directs its efforts toward the discovery and clinical development of biological drugs. The company secured approximately ¥600 million (US$89 million) in a series B funding round in early 2023, with the proceeds intended to advance its clinical trials, support drug discovery, and explore in-licensing opportunities .

The company's business model is centered on internal research and development, supplemented by strategic collaborations and acquisitions to build its product pipeline . It generates value by advancing drug candidates through the rigorous phases of clinical trials with the ultimate goal of commercialization. The company targets both the domestic Chinese market and international markets, having received FDA approval in the U.S. for a phase I trial of one of its candidates .

CR Biopharm's therapeutic focus encompasses a range of significant disease areas, including cardiovascular conditions, oncology, ophthalmology, autoimmune diseases, respiratory illnesses, and hematologic cancers . Its pipeline features several candidates in clinical development. A notable asset is CRB-4101, a selective oral small-molecule factor XI (FXIa) inhibitor aimed at preventing venous thromboembolism; it was approved by the FDA for a phase I trial in the United States in late 2022 . The company also has CRB-1301 in a phase III trial for treating acute ischemic stroke, positioning it to potentially enter a market segment in China currently dominated by imported drugs . Additionally, through a partnership with U.S.-based Ab Studio Inc., CR Biopharm acquired worldwide rights to develop and commercialize a neutralizing antibody project against COVID-19 .